GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)

BOM:500660 Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	6,945	11,021	5,388	641.71	349.41	2,862
Short-Term Investments	15,240	2,638	8,410	9,794	11,009	21,791
Trading Asset Securities	-	13,910	11,182	8,132	5,183	3,656
Cash & Short-Term Investments	22,185	27,568	24,981	18,568	16,541	28,309
Cash Growth	7.65%	10.36%	34.54%	12.25%	-41.57%	148.94%
Accounts Receivable	3,394	2,731	2,925	2,221	1,924	2,052
Other Receivables	-	345.3	682.8	1,275	1,373	715.31
Receivables	3,394	3,076	3,608	3,496	3,297	2,768
Inventory	5,544	4,576	4,817	5,250	4,600	5,347
Prepaid Expenses	-	190.71	188.86	206.18	149.6	139.26
Other Current Assets	1,178	651.31	503.25	463.33	355.04	517.62
Total Current Assets	32,301	36,062	34,099	27,984	24,943	37,080
Property, Plant & Equipment	3,208	3,064	2,839	3,107	3,151	3,254
Long-Term Investments	8.7	8.93	0.27	0.27	0.27	0.15
Other Intangible Assets	60	65.56	133.32	235.54	340.91	344.97
Long-Term Deferred Tax Assets	1,289	1,338	1,409	1,463	1,335	1,131
Other Long-Term Assets	2,819	2,699	2,601	2,776	2,795	2,621
Total Assets	39,686	43,239	41,081	35,566	33,266	46,333

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	5,587	5,702	7,082	6,254	4,278	5,793
Accrued Expenses	-	1,521	2,215	1,655	1,482	4,622
Current Portion of Leases	225.7	159.99	74.59	121.96	120.84	124.53
Current Income Taxes Payable	5,787	5,460	5,245	2,986	2,962	2,962
Other Current Liabilities	6,459	4,947	4,434	4,233	4,421	3,483
Total Current Liabilities	18,058	17,791	19,052	15,249	13,264	16,984
Long-Term Leases	166.8	172.73	24.92	64.69	34.55	76.24
Pension & Post-Retirement Benefits	-	786.89	868.04	802.99	793.71	794.7
Other Long-Term Liabilities	2,651	1,814	1,623	1,673	1,761	1,848
Total Liabilities	20,875	20,564	21,568	17,790	15,853	19,703

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	1,694	1,694	1,694	1,694	1,694	1,694
Retained Earnings	-	21,616	18,371	16,549	15,920	25,210
Comprehensive Income & Other	17,116	-636.04	-552.3	-467.04	-201.58	-274.96
Shareholders' Equity	18,811	22,674	19,513	17,776	17,413	26,630
Total Liabilities & Equity	39,686	43,239	41,081	35,566	33,266	46,333

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	392.5	332.72	99.51	186.65	155.39	200.77
Net Cash (Debt)	21,793	27,235	24,882	18,382	16,386	28,108
Net Cash Growth	7.61%	9.46%	35.36%	12.18%	-41.70%	154.93%
Net Cash Per Share	128.96	160.77	146.88	108.51	96.73	165.92
Filing Date Shares Outstanding	169.38	169.41	169.41	169.41	169.41	169.41
Total Common Shares Outstanding	169.38	169.41	169.41	169.41	169.41	169.41
Working Capital	14,244	18,271	15,047	12,735	11,679	20,096
Book Value Per Share	111.06	133.85	115.19	104.93	102.79	157.19
Tangible Book Value	18,751	22,609	19,380	17,541	17,072	26,285
Tangible Book Value Per Share	110.70	133.46	114.40	103.54	100.77	155.16
Land	-	37	37	37	36.8	22.49
Buildings	-	1,140	1,121	1,099	1,084	1,041
Machinery	-	4,440	4,401	4,489	4,244	3,937
Construction In Progress	-	329.26	143.2	139.3	203.12	305.02

Data Source: S&P Global Market Intelligence Last updated: Nov 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 5, 2026

Data Sources Report a data error